The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Nurtec ODT (rimegepant) on May 27, 2021. This significant regulatory action, identified as NDA 212728 S-6, specifically pertains to the efficacy of the medication, reinforcing its therapeutic profile. The approval was for an application submitted by the sponsor, Pfizer.
Background
Rimegepant, marketed under the brand name Nurtec ODT, received this supplemental approval from the FDA. The application, designated as NDA 212728 S-6, was submitted by its sponsor, Pfizer. This type of supplemental application typically provides additional data or information regarding the drug's effectiveness, which can lead to updates in its approved labeling or a deeper understanding of its therapeutic benefits within its existing or potentially new indications. The "Class: Efficacy" designation highlights that the core of this approval relates to the drug's demonstrated ability to produce the desired therapeutic effect.
What this means
This supplemental approval for Nurtec ODT (rimegepant) by the FDA signifies a further validation or enhancement of the drug's established efficacy profile. While the specific details of the efficacy supplement are not provided in the available data, such approvals are crucial for refining the understanding of a drug's performance. They can lead to updates in prescribing information, potentially expanding the patient population for whom the drug is indicated, or providing more detailed guidance on its use. For clinicians, this means updated information regarding how rimegepant can be effectively utilized in patient care. For researchers, it adds to the body of evidence supporting the drug's mechanism and clinical utility. Patient advocates can use this information to better understand the scope of treatment options available. The approval underscores the ongoing regulatory oversight and continuous evaluation of drug effectiveness post-initial market authorization.
Source
The information concerning this supplemental approval was officially released by the U.S. Food and Drug Administration (FDA). The details for the supplemental new drug application (NDA) 212728 S-6, pertaining to Nurtec ODT (rimegepant sulfate), were recorded with an event date of 2021-05-27. This regulatory update is publicly accessible on the official FDA website, specifically via accessdata.fda.gov, which serves as a primary source for drug approval information.